Yıl: 2019 Cilt: 17 Sayı: 1 Sayfa Aralığı: 48 - 56 Metin Dili: Türkçe İndeks Tarihi: 10-06-2020

Koroner Arter Hastalığında Yeni Parametreler: Oksidatif Stres Belirteçleri

Öz:
Amaç: Oksidatif stres parametreleri olarak malondialdehit (MDA) ve Proteinlerin İleri Oksidasyon Ürünleri (AOPP) düzeylerinin koroner arter hastalığı (KAH)’nın derecesini belirlemede kullanılıp kullanılamayacağını araştırmaktır.Gereç ve Yöntem: Koroner arter hastalığı şüphesiyle koroner anjiografi yapılan hastalar, bir stenoz skorlaması olan Gensini skorlama sistemi ile hastalığın derecesine göre üç gruba ayrıldı. Gensini skoru 0-4 arasında olan hastalar kontrol grubu (Grup-I) olarak kabul edildi. Gensini skoru 5-35 arasında olan hastalar Grup-II ve Gensini skoru >35 olan hastalar da Grup-III olarak belirlendi. Plazma MDA düzeyleri; MDA hidrazonunun, HPLC’ de kromatografik olarak ayrıştırılması metodunun bir modifikasyonu ile, plazma AOPP düzeyleri ise spektrofotometrik yöntem ile ölçüldü.Bulgular: Çalışmamızda oksidatif stres göstergelerinden biri olan plazma MDA düzeylerinde, Grup-I ile Grup-III arasında istatistiksel olarak anlamlı bir fark tespit edildi (p=0.048). Plazma AOPP düzeylerinde ise, Grup-I ile Grup-III ve Grup-II ile Grup-III arasında istatistiksel olarak anlamlı fark tespit edildi (sırasıyla, p=0.034, p=0.039). Katılımcıların Gensini skorları ile MDA düzeyleri ve AOPP düzeyleriarasında pozitif korelasyon olduğu gözlendi (sırasıyla r=0.271, p=0.021; r=0.241, p=0.041).Sonuç: Çalışmamız sonucunda koroner arter hastalığı derecesi ile AOPP ve MDA düzeyleri arasında bir ilişki belirledik. Koroner arter hastalığının derecesi arttıkça bu parametrelerin düzeylerinde de artma gözlenmiş olup, AOPP ve MDA analizinin koroner arter hastalığının derecesini belirlemede kullanılabileceği düşünülmüştür.
Anahtar Kelime:

New Parameters of Coronary Artery Diseases: Oxidative Stress Markers

Öz:
Aim: The aim was to determine if the malondialdehyde (MDA) and advanced oxidation products of protein (AOPPs) levels, which are oxidative stress parameters, can be used to determine the degree of coronary artery disease.Materials and Methods: The patients undergoing coronary angiography with the suspicion of coronary artery disease were divided into three groups based on the severity of disease by a stenosis scoring, Gensini scoring system. The patients with a Gensini score between 0 and 4 were assigned as Group I (control group). Those with a Gensini score between 5-35 were assigned as Group II and those having Gensini score >35 were as Group III. Plasma MDA levels were measured using a modification of the chromatographic degradation of MDA hydrazone by high performance liquid chromotagraphy, whereas plasma AOPP levels were measured spectrophotometrically.Results: In the present study, a statistically significant difference was found between Group I and Group III in terms of plasma MDA levels, which is an indicator of stress (p=0.048). There were statistically significant differences between Group I and Group III and between Group II and Group III in terms of plasma AOPP levels (p=0.034, p=0.039, respectively). It was observed that the Gensini scores of participants had positive correlations with MDA and AOPP levels (r=0.271, p=0.021; r=0.241, p=0.041, respectively).Conclusion: In the present study, it was determined that the severity of coronary artery disease has a relationship with AOPP and MDA levels. An increase was observed in the levels of these parameters as the severity of coronary artery disease increased.It is concluded that the AOPP and MDA levels can be used to determine the degree of coronary artery disease.
Anahtar Kelime:

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
  • 1. Sargowo D, Ovianti N, Susilowati E, Ubaidillah N, Widya Nugraha A, Vitriyaturrida, Siwi Proboretno K, et al. The role of polysaccharide peptide of Ganoderma lucidum as a potent antioxidant against atherosclerosis in high risk and stable angina patients. Indian Heart J 2018 Sep - Oct;70(5):608- 614.
  • 2. Sokolow M, Mc Lilroy M, Cheitlin MD. Coronary Heart Disease. In: Clinical Cardiology, A Lange Medical Book. 15th ed. 1990. p.145-224.
  • 3. Wassmann S, Wassmann K and Nickenig G. Modulation of Oxidant and Antioxidant Enzyme Expression and Function in Vascular Cells. Hypertension 2004;44:381-386.
  • 4. Therond P, Bonnefont-Rousselot D, Davit-Spraul A, Conti M, Leqrand A. Biomarkers of oxidative stress: an analytical approach. Curr Opin Clin Nutr Metab Care 2000;3: 373-84.
  • 5. Nourooz-Zadeh J. Ferrous ion oxidation in presence of xylenol orange for detection of lipid hydroperoxides in plasma. Methods Enzymol 1999;300:58- 62.
  • 6. Valdez LB, Arnaiz SL, Bustamante J, Alvarez S, Costa LE, Boveris A. Free radical chemistry in biological systems. Biol Res 2000;33: 1-8.
  • 7. Halliwell B, Gutteridge JMC. Free radicals in biology and medicine. Newyork: Oxford University Press Inc; 2007.p.55-79.
  • 8. Witko-Sarsat V, Friedlander M, Capeillere-Blandin C, Nguyen-Khoa T, Nguyen AT, Zingraff J, et al. Advanced oxidation protein products as a novel marker of oxidative stress in uremia. Kidney Int 1996;49(5):1304-13.
  • 9. Descamps-Latscha B, Witko-Sarsat V. Importance of oxidatively modified proteins in chronic renal failure. Kidney Int Suppl 2001;78:108-13.
  • 10. Gensini GG. Coronary arteriogaphy. Mount Kisco (NY): Futura Publishing Co; 1975.
  • 11. Pilz J, Meineke I, Gleiter CH. Measurement of free and bound malondialdehyde in plasma by Highperformance liquid chromatography as the 2,4- dinitrophenylhydrazine derivative. J Choromatogr B 2000;742:315-325.
  • 12. Witko-Sarsat V, Nguyen-Khoa T, Jungers P, Drueke T, Descamps-Latscha B. Advanced oxidation protein products as a novel molecular basis of oxidative stres in uremia. Nephrol Dial Transplant 1999;14(1):76-78.
  • 13. Hennekens CH. Increasing burden of cardiovascular disease. Current knowledge and future firections for research on risc factors. Circulation 1998;97:1095- 1102.
  • 14. Westhuyzen J. The oxidation hypothesis of atherosclerosis: Ann Clin Lab Sci 1997;27:1-9.
  • 15. Uysal M. Ateroskleroz, kalp-damar hastalıkları ve serbest radikaller. Aktüel Tıp Dergisi 2000;5:15-21.
  • 16. Glavind J, Hartmann S, Clemmesen J, Jessen KE, Dam H. Studies on the role of lipid peroxides in human pathology. II. The presence of peroxidized lipids in the atherosclerotic aorta. Acta Pathol 1952;30:1-6.
  • 17. Doğru-Abbasoğlu S, Kanbağlı O, Bulur H, Babalık E, Öztürk S, Aykaç-Toker G, et al. Lipid peroxides and antioxidant status in serum of patients with angiographically defined coronary atherosclerosis. Clin Biochem 1999;32:671-672.
  • 18. Uysal M, Kutalp G, Seçkin S. The effect of cholesterol feeding on lipid peroxide, glutathione, glutathione peroxidase and glutathione transferase in the liver of rats. Intern J Vit Nutr Res 1988;58:339-342.
  • 19. Balkan J, Kanbağlı O, Hatipoğlu A, Kücük M, Cevikbaş U, Aykaç-Toker G, et al. Improving effect of dietary taurine supplementation on the oxidative stress and lipid levels in the plasma, liver and aorta of rabbits fed on a high-cholesterol diet. Biosci Biotechnol Biochem 2002; 66:1755-1758.
  • 20. De La Cruz JP, Quintero L, Villalobos MA, De La Cuesta FS. Lipid peroxidation and glutathione system in hyperlipemic rabbits: influence of olive oil administration. Biochem Biophys Acta 2000;1485:36-44.
  • 21. Singh Z, Karthigesu IP, Singh P, Kaur R. Use of Malondialdehyde as a Biomarker for Assessing Oxidative Stress in Different Disease Pathologies: a Review.Iranian Journal of Public Health 2014;43(3):7-16.
  • 22. Upston JM, Niu X, Brown AJ, Mashima R, Wang H, Senthilmohan R, et al. Disease stage-dependent accumulation of lipid and protein oxidation products in human atherosclerosis. Am J Pathol 2002;160:701-710.
  • 23. Yaghoubi A, Ghojazadeh M, Abolhasani S, Alikhah H, and Khaki-Khatibi F. Correlation of Serum Levels of Vitronectin, Malondialdehyde and Hs- CRP With Disease Severity in Coronary Artery Disease.J Cardiovasc Thorac Res 2015;7(3): 113–117.
  • 24. Cavalca V, Cighetti G, Bamonti F, Loaldi A, Bortone L, Novembrino C, et al. Oxidative Stress and Homocysteine in Coronary Artery Disease. Clinical Chemistry 2001;47(5):887-892.
  • 25. Garelnabi M, Gupta V, Mallika V and Bhattacharjee J. Platelets Oxidative Stress in Indian Patients with Ischemic Heart Disease. Journal of Clinical Laboratory Analysis 2010;24:49-54.
  • 26. Tamer L, Sucu N, Polat G, Ercan B, Aytacoglu B, Yücebilgiç G, et al. Decreased Serum Total Antioxidant Status and Erythrocyte-Reduced Glutathione Levels Are Associated with Increased Serum Malondialdehyde in Atherosclerotic Patients. Archives of Medical Research 2002;33:257-260.
  • 27. Rasool M, Malik A, Butt TT,Ashraf MA,Rasool R,Zahid A, et al.mplications of advanced oxidation protein products (AOPPs), advanced glycation end products (AGEs) and other biomarkers in the development of cardiovascular diseases. Saudi Journal of Biological Sciences 2019;26(2):334-339.
  • 28. Kaneda H, Taguchi J, Ogasawara K, Aizawa T, Ohno M. Increased Level of Advanced Oxidation Protein Products in Patients With Coronary Artery Disease. Atherosclerosis 2002;162:221-225.
  • 29. Descamps-Latscha B, Witko-Sarsat V, Nguyen-Khoa T, Nguyen AT, Gausson V, Mothu N, et al. Advanced Oxidation Protein Products as Risk Factors for Atherosclerotic Cardiovascular Events in Nondiabetic Predialysis Patients. American Journal of Kidney Diseases 2005;45(1):39-47.
  • 30. Skvarilova M, Bulava A, Stejskal D, Adamovska S, Bartek J. Increased Level of Advanced Oxidation Products (AOPP) as a Marker of Oxidative Stres in Patients with Acute Coronary Syndrome. Biomed Papers 2005;149(1):83-87.
APA ERÇİN U, Bilgihan A, ERKAN A, YÜCEL H (2019). Koroner Arter Hastalığında Yeni Parametreler: Oksidatif Stres Belirteçleri. , 48 - 56.
Chicago ERÇİN UĞUR,Bilgihan Ayse,ERKAN Aycan Fahri,YÜCEL Hayati Koroner Arter Hastalığında Yeni Parametreler: Oksidatif Stres Belirteçleri. (2019): 48 - 56.
MLA ERÇİN UĞUR,Bilgihan Ayse,ERKAN Aycan Fahri,YÜCEL Hayati Koroner Arter Hastalığında Yeni Parametreler: Oksidatif Stres Belirteçleri. , 2019, ss.48 - 56.
AMA ERÇİN U,Bilgihan A,ERKAN A,YÜCEL H Koroner Arter Hastalığında Yeni Parametreler: Oksidatif Stres Belirteçleri. . 2019; 48 - 56.
Vancouver ERÇİN U,Bilgihan A,ERKAN A,YÜCEL H Koroner Arter Hastalığında Yeni Parametreler: Oksidatif Stres Belirteçleri. . 2019; 48 - 56.
IEEE ERÇİN U,Bilgihan A,ERKAN A,YÜCEL H "Koroner Arter Hastalığında Yeni Parametreler: Oksidatif Stres Belirteçleri." , ss.48 - 56, 2019.
ISNAD ERÇİN, UĞUR vd. "Koroner Arter Hastalığında Yeni Parametreler: Oksidatif Stres Belirteçleri". (2019), 48-56.
APA ERÇİN U, Bilgihan A, ERKAN A, YÜCEL H (2019). Koroner Arter Hastalığında Yeni Parametreler: Oksidatif Stres Belirteçleri. Türk Klinik Biyokimya Dergisi, 17(1), 48 - 56.
Chicago ERÇİN UĞUR,Bilgihan Ayse,ERKAN Aycan Fahri,YÜCEL Hayati Koroner Arter Hastalığında Yeni Parametreler: Oksidatif Stres Belirteçleri. Türk Klinik Biyokimya Dergisi 17, no.1 (2019): 48 - 56.
MLA ERÇİN UĞUR,Bilgihan Ayse,ERKAN Aycan Fahri,YÜCEL Hayati Koroner Arter Hastalığında Yeni Parametreler: Oksidatif Stres Belirteçleri. Türk Klinik Biyokimya Dergisi, vol.17, no.1, 2019, ss.48 - 56.
AMA ERÇİN U,Bilgihan A,ERKAN A,YÜCEL H Koroner Arter Hastalığında Yeni Parametreler: Oksidatif Stres Belirteçleri. Türk Klinik Biyokimya Dergisi. 2019; 17(1): 48 - 56.
Vancouver ERÇİN U,Bilgihan A,ERKAN A,YÜCEL H Koroner Arter Hastalığında Yeni Parametreler: Oksidatif Stres Belirteçleri. Türk Klinik Biyokimya Dergisi. 2019; 17(1): 48 - 56.
IEEE ERÇİN U,Bilgihan A,ERKAN A,YÜCEL H "Koroner Arter Hastalığında Yeni Parametreler: Oksidatif Stres Belirteçleri." Türk Klinik Biyokimya Dergisi, 17, ss.48 - 56, 2019.
ISNAD ERÇİN, UĞUR vd. "Koroner Arter Hastalığında Yeni Parametreler: Oksidatif Stres Belirteçleri". Türk Klinik Biyokimya Dergisi 17/1 (2019), 48-56.